ライフサイエンスコーパス: minor histocompatibility antigen

1 ted in this issue employed the redesign of a minor histocompatibility antigen.

2 , a thirteen-residue, maternally transmitted minor histocompatibility antigen.

3 tinoic acid early transcript (Rae1) and H-60 minor histocompatibility antigen.

4 yngeneic antigen-presenting cells presenting minor histocompatibility antigens.

5 ing for major histocompatibility antigens or minor histocompatibility antigens.

6 ls in the development of humoral immunity to minor histocompatibility antigens.

7 ediated by donor T cells that recognize host minor histocompatibility antigens.

8 lografts that confront the host with foreign minor histocompatibility antigens.

9 were oligoclonal, pointing to a response to minor histocompatibility antigens.

10 yeloid-specific differentiation antigens and minor histocompatibility antigens.

11 The hypothesis that ICAM-1 acts as a minor histocompatibility antigen and that anti-ICAM-1 an

12 cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damag

13 xpansion of Tregs against major and possibly minor histocompatibility antigens and predict the feasib

14 genes and subsequent reduced presentation of minor histocompatibility antigens and reduced ligation o

15 ansplant is acquired tolerance of allogeneic minor histocompatibility antigens and that posttransplan

16 Immune responses to minor histocompatibility antigens are poorly understood

17 PK3 and the shared antigens do not represent minor histocompatibility antigens, as their sequences ar

18 acute CD4+ T cell-mediated GVHD across this minor histocompatibility antigen barrier depends on the

19 helper-deficient CD8(+) T-cell response to a minor histocompatibility antigen by phenotypic and in vi

20 Minor histocompatibility antigens contribute to the cont

21 Here we describe a human minor histocompatibility antigen created by a polymorphi

22 On the other hand, the importance of minor histocompatibility antigens derived from nonhemato

23 ed this alloimmune syndrome in recipients of minor histocompatibility antigen disparate donor cells,

24 When transplanted into minor histocompatibility antigen-disparate allogeneic re

25 row irradiation chimeras across the multiple minor histocompatibility antigen-disparate, C57BL/6-->BA

26 of cases across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-d cou

27 induced across a two-haplotype class I plus minor histocompatibility antigen disparity by a 12-day c

28 onor T cells that are specific for recipient minor histocompatibility antigens encoded by Y-chromosom

29 Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chrom

30 to donor human leukocyte antigen molecules, minor histocompatibility antigens, endothelial cells, RB

31 duce ACAID, but soluble and cell-associated (minor histocompatibility) antigens generated cell-associ

32 etinoic acid early inducible (RAE-1) and H60 minor histocompatibility antigen genes on mouse chromoso

33 totoxic T cell clones specific for the human minor histocompatibility antigen H-Y and restricted by H

34 suggested that recipient mismatching for the minor histocompatibility antigen HA-1 is associated with

35 For minor histocompatibility antigens HA-1 and HA-2, normal

36 atched BALB.B spleen cells, despite multiple minor histocompatibility antigen (HA) differences.

37 Indirect presentation of minor histocompatibility antigens (HA) as revealed by cr

38 ation produces HvG against the male specific minor histocompatibility antigen HY.

39 ed the HLA-B27-restricted CTL response to HY minor histocompatibility antigens in rats and mice trans

40 ors, including recognition of sex-determined minor histocompatibility antigens, influence of sex horm

41 In a single minor histocompatibility antigen (male to female)-depend

42 In addition, a better understanding of minor histocompatibility antigens may lead to more targe

43 of RBC products induced BMT rejection across minor histocompatibility antigen (mHA) barriers.

44 ined the immune response to DBY, a model H-Y minor histocompatibility antigen (mHA) in a male patient

45 C with grafts supplemented with T cells in a minor histocompatibility antigen (mHA)-mismatched mouse

46 rences in susceptibility to immune pressure, minor histocompatibility antigen (mHa)-specific T-cell l

47 Human minor histocompatibility antigens (mHA) and clinically r

48 Next, we immunized the donor to the minor histocompatibility antigens (mHA) of the recipient

49 Minor histocompatibility antigen (mHag) discordances hav

50 astocytoma in a murine model of MHC-matched, minor histocompatibility antigen (mHAg)-mismatched bone

51 Minor histocompatibility antigens (mHAg's) are peptides

52 Minor histocompatibility antigens (mHags) are immunogeni

53 le GVHD because of the presence of recipient minor histocompatibility antigens (mHAgs) in whole-cell

54 er of donor T cells that recognize recipient minor histocompatibility antigens (mHAgs) is a potential

55 he priming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor v

56 Minor histocompatibility antigens (mHAgs) present a sign

57 T cell recognition of minor histocompatibility antigens (mHags) underlies allo

58 herited major histocompatibility complex and minor histocompatibility antigens (mHAgs).

59 ced primarily by donor T-cell recognition of minor histocompatibility antigens (mHAgs).

60 Minor histocompatibility antigens (mHAs) are known targe

61 Alloreactive donor T cells against host minor histocompatibility antigens (mHAs) cause graft-ver

62 le for increased rejection is likely against minor histocompatibility antigens (mHAs).

63 T(M) from donors vaccinated against a single minor histocompatibility antigen (miHA) expressed by leu

64 cient B6 (H-2(b)) recipients primed to donor minor histocompatibility antigen (MiHA) prior to BM tran

65 Minor histocompatibility antigen (miHA) vaccines have th

66 smatched, CD4-driven murine GVHD model and a minor histocompatibility antigen (MiHA)-mismatched, CD8-

67 cing alloreactive T cell responses targeting minor histocompatibility antigens (MiHA) expressed on ma

68 mice and the interaction of these cells with minor histocompatibility antigen- (miHA-) mismatched CD8

69 SCT, CD8+ stem cell memory T cells targeting minor histocompatibility antigens (MiHAs) expressed by r

70 r magnitude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients wi

71 s) initiate GVHD by directly presenting host minor histocompatibility antigens (miHAs) to donor CD8 c

72 onor and recipient were incompatible at many minor histocompatibility antigens (minor H Ags), the CD8

73 Minor histocompatibility antigens (minor H antigens) are

74 -dependent GVHD in a mouse model across only minor histocompatibility antigens (minor H antigens).

75 test the role of donor Stat1 in MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatc

76 study the mechanisms of DLI in MHC-matched, minor histocompatibility antigen-mismatched allogeneic c

77 histocompatibility complex-matched multiple minor histocompatibility antigen-mismatched alloHCT usin

78 usion may not apply to MHC-matched, multiple minor histocompatibility antigen-mismatched alloSCT, the

79 In both a minor histocompatibility antigen-mismatched as well as a

80 Recipients were H-2-matched, minor histocompatibility antigen-mismatched C57BL/6 mice

81 ed, single Y chromosome-encoded, or multiple minor histocompatibility antigen-mismatched hematopoieti

82 r Histocompatibility Antigen Complex-matched minor Histocompatibility Antigen-mismatched murine model

83 platelets, and we report that transfusion of minor histocompatibility antigen-mismatched platelets in

84 play an important role in clinical GVHD in a minor histocompatibility antigen-mismatched setting.

85 major histocompatibility complex-matched and minor histocompatibility antigen-mismatched unrelated do

86 te infusions (DLIs) were incorporated into a minor histocompatibility antigen-mismatched, T cell-depl

87 ansplantation, donors' T cells can recognize minor histocompatibility antigens on recipient cells and

88 eved to be mediated by T-cell recognition of minor histocompatibility antigens on recipient cells.

89 The inclusion of SNPs that encode minor histocompatibility antigens or other genetic polym

90 Minor histocompatibility antigens play a significant rol

91 The GVL effect is directed against minor histocompatibility antigens shared by normal and l

92 ificantly suppressed the clonal expansion of minor histocompatibility antigen-specific CD8 T cells du

93 pleen cells do not inhibit allogeneic MHC or minor histocompatibility antigen-specific CTL production

94 bone marrow is not matched in the clinic for minor histocompatibility antigens, such as those carried

95 ying a murine model that uses differences in minor histocompatibility antigens to generate Scl GVHD.

96 grafts, skin differing from the host only by minor histocompatibility antigens undergoes slower (i.e.

97 matched donor MHC class I and II, and of H-Y minor histocompatibility antigen was assessed by quantif

98 kin and bone marrow, mismatched for multiple minor histocompatibility antigens, was induced in Fas mu

99 stent with a response to immunodominant host minor histocompatibility antigens, we detected oligoclon

100 for disparities in cytoplasmically inherited minor histocompatibility antigens, we examined one hyper

101 a strong genetic disparity in both major and minor histocompatibility antigens were used for transpla

102 cognition of these hematopoietically derived minor histocompatibility antigens will induce significan

103 Minor histocompatibility antigens with expression restri